Chapter 23: Schedule of systematic vaccinations of adolescents and adults is recommended by the Spanish Society of Preventive Medicine, Public Health and Hygiene (2009 Updates);Capítulo 23 calendario de vacunaciones sistemáticas del adolescente y adulto recomendado por la sociedad española de medicina preventiva, salud pública e higiene (actualización del año 2009)

Medicina Preventiva

Volumn 16, Issue 1, 2010, Pages 76-86

  Salleras, L ^a   Campins, M ^a   Castrodeza, J ^a   Dominguez A ^a   Dominguez V ^a   Fernandez Crehuet J ^a   Fernandez S ^a   De Juanes, J R ^a   Pastor, V ^a   Saenz, M C ^a  

^a Salud Pública e Higiene ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953557624     PISSN: 11352841     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (177)

1. Comité de Vacunas de la Sociedad Española de Medicina Preventiva, Salud Pública e Higiene. L. Salleras (Coordinador), JM. Bayas, F. Calbo, M. Campins, J. Castrodeza, A. Cerrillo, M. Conde, A. Domínguez, V. Domínguez, JA. Forcada, A. Gil, JR. de Juanes, MC Saenz. Calendario de vacunaciones sistemáticas del adulto y recomendaciones de vacunación para los adultos que presentan determinadas condiciones médicas, exposiciones o conductas de riesgo. Vacunas 2006; 7 (supl. 1): 1-173.
2. Comité de Vacunas de la Sociedad Española de Medicina Preventiva, Salud Pública e Higiene. L. Salleras (Coordinador), JM. Bayas, F. Calbo, M. Campins, J. Castrodeza, A. Cerrillo, M. Conde, A. Domínguez, V. Domínguez, JA. Forcada, A. Gil, JR. de Juanes, MC Saenz. Puesta al día: "Vacunación antitosferina de los adolescentes y adultos". Vacunas. 2007; 8: 38-47.
3. Salleras L. Vacunación frente a la tos ferina en el adolescente y adulto: una estrategia marcada por la epidemiología. Vacunas 2007; 8: 1-2.
4. Pickering LK, Orenstein WA. Development of pediatric vaccine recommendations and policies. Semin Pediatr Infect Dis 2002; 13: 148-154
5. Rabinovich NR, Orenstein WA. Vaccines. Overview. Epidemiol Rev 1999; 21: 1-6.
6. Salleras L. El futuro del calendario vacunal. Vacunas 2003; 4 (supl. l): 42-53.
7. Rodríguez Torres A, Castrodeza J, Ortiz de Lejarazu R. Vacuna antigripal. En: Salleras Sanmartí L, ed. Vacunaciones preventivas. 2 edición. Barcelona: Masson 2003; p. 321-362
8. De Juanes JR. Influenza: key issues and immunisation. Chemist 2002; 2: 4-16.
9. Domínguez A, Salleras L, Cardeñosa N, Ciruela P, Carmona G, Martinez A et al. The epidemiology of invasive Streptococcus pneumoniae disease in Catalonia (Spain). A hospital-based study. Vaccine 2002; 3250: 1-6.
10. Bruguera M, Sánchez Tapias JM. Epidemiología de la hepatitis B en España. Med Clin (Bare) 1990; 95: 470-475
11. Bruguera M, Forns X. Epidemiología actual de las hepatitis virales: ¿quién las padece y quien puede protegerse? Enferm Infec Microbiol Clin 2004; 22: 443-447
12. Castellsagué X, Bosch FX. Vacunas frente al virus del papiloma humano. Enferm Infecc Microbiol Clin 2007; 25(supl. 5): 65-77.
13. Salleras L, Taberner JL, Batalla J, Urbiztondo L, Rodríguez G, Plans P et al. Enfermedades prevenibles mediante vacunaciones sistemáticas. Evaluación de los objetivos del Plan de Salud para el año 2000. Med Clin (Bare) 2003; 121 (supl. 1): 74-78
14. Domínguez A, Tomer N, Barrabeig I, Rovira A, Rius C, Caylà J et al. Large measles outbreak in a community with high vaccination coverage. Clin Infect Dis 2008; 47: 1143-1149
15. Perucha M, Ramalle-Gómara E, Lezaun ME, Blanco A, Quiñones C, Blasco M et al. Measles outbreak in children under 15 months of age in La Rioja, Spain 2005-2006. Euro Sureill 2006; 11: 202.
16. Carnicer-Pont D, Peña-Rey I, de Aragón VM, de Ory F, Dominguez A, Tomer N et al. Eliminating congenital rubella syndrome in Spain: does massive immigration have any influence? Eur J Public Health. 2008; 18: 688-690
17. García L. Outbreak of rubella in the Madrid region, Spain, 2005. Euro Surveill 2005; 10: E050707.2.
18. Garcia L. Measles outbreak in the region of Madrid, Spain, 2006. Euro Surveill 2006; 11: E060330.3.
19. Martínez-Torres AO, Mosquera MM, Sanz JC, Ramos B, Echevarría JE. Phylogenetic analysis of rubella virus strains from an outbreak in Madrid, Spain, from 2004 to 2005. J Clin Microbiol 2009; 47: 158-163
20. Salleras L, Domínguez A. Evaluación de la eficacia de las vacunas y de la efectividad de los programas de vacunaciones. En: Salleras L, editor. Vacunaciones preventivas. 2 ed. Barcelona: Masson, 2003; p. 781-800.
21. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analysis of pneumococcal vaccine in elderly and high risk adults. Vaccine 2004; 22: 927-946
22. Campins M, Moraga FA. Vacuna antipertussis. En: Salleras L, editor. Vacunaciones preventivas. 2 edición. Barcelona: Masson 2003; p. 139-162
23. De Juanes JR, Gil A, González A, Arrazola MP, Sanmartín M, Esteban J. Seroprevalence of pertussis antibody among health care personnel in Spain. Eur J Epidemiol 2004; 19: 69-72. (Pubitemid 38250056)
24. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N et al. New pertussis vaccination strategies beyond infancy: Recommendations by the Global Pertussis Initiative. Clin Infect Dis 2004; 39: 1802-1809
25. Gardner P. Issues related to the decennial tetanus-diphteria toxoid booster recommendations in adults. Infect Dis Clin North Am 2001; 15: 143-153
26. Mathias RG, Schechter MT. Booster inmunizationfor diphtheria and tetanus no evidence for need in adults. Lancet 1985; 1: 1089-1091
27. Simonsen O, Kjelgelsen K, Heron I. Inmunity against tetanus and effect of revaccination 25-30 years after primary vaccination. Lancet 1984; 2: 1240-1242
28. CDC. Recommended adult immunization schedule - United States, 2009. MMWR 2009; 57: Q1-Q4.
29. CDC. Recommended immunization schedule for persons aged 0 through 18 years - United States, 2009. MMWR 2009; 57; Q1-Q4.
30. CDC. Preventing tetanus, diphteria and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006; 55 (RR 17): 1-37.
31. Wassilak SGF, Roper MH, Kretsinger K, Orenstein WA. Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines fifth edition. Philadelphia: Saunders; 2008: 805-839
32. Gidengil CA, Sandora TJ, Lee GM. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA. Expert Rev Vaccines 2008; 7: 621-638
33. LaForce FM, Young LS, Bennett JV. Tetanus in the United States (1965-1966). N Engl J Med 1969: 280: 569-574
34. Pascual FB, McGinley E, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance - United States, 1998-2000. MMWR 2003; (SS-3): 1-8.
35. Pryor T, Onarecker C, Coniglione T. Elevated antitoxin titers in a man with generalized tetanus. J Fam Pract 1997; 44: 299-303.
36. Abrahamian FM, Pollack CV Jr, LoVecchio F, Nanda R and Carlson RW. Fatal tetanus in a drug abuser with "protective" antitetanus antibodies. J Emerg Med 2000; 18: 189-193
37. Long AP, Sartwell PE. Tetanus in the US Army in the World War II. Bull US Army Med Dept 1947; 7: 371-385
38. Murphy KJ. Fatal tetanus with brain-stem involvement and myocarditis in an exserviceman. Med J Aust 1970; 57: 542-544
39. McQuillan GM, Kruszon-Moran D, Deforest A, Chu Sy, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136: 660-666
40. Vacunación en adultos. Recomendaciones. Vacuna de difteria y tétanos. Actualización 2009. Ministerio de Sanidad Política Social http://www.msc.es/ciudadanos/proteccionSalud/vacunaciones/docs/ retanosDifteria 2009.pdf
41. Estudio seroepidemiológico. Situación de las enfermedades vacunables en España. Ministerio de Sanidad y Consume. ISC III. Centro Nacional de Epidemiología. España 2000.
42. Vidal J, Salleras L. Vacuna antitetánica. En: Vacunaciones preventivas. Principios y aplicaciones, 2 ed. Masson, Barcelona 2003.
43. Domínguez A, Plans P, Costa J, Espuñes J, Cardeñosa N, Salleras L et al. The seroepidemiology of tetanus in Catalonia, Spain. Med Microbiol Immunol 2007; 196: 115-119
44. Salleras L, Domínguez A. Políticas vacunales oficiales en España. En: Plotkin SA, Orenstein WA, Picazo JJ, Offit PA, editores. Vacunas. 1. ed. española. Acindes, Madrid 2007.
45. Bayas JM, Vilella A, Bertran MJ, Vidal J, Batalla J, Asenjo MA, Salieras Ll. Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary?. Epidemiol Infect 2001; 127: 451-460
46. Bayas JM, Vilella A. Vacunaciones del adulto. En: Salleras L, editor. Vacunaciones preventivas. 2 ed. Barcelona: Masson 2003; p. 849-865
47. Vitek CR, Wharton M. Diphtheria Toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Saunders; 2008: p. 139-156.
48. WHO. Diphtheria vaccine. WHO position paper. Wkly Epidemiol Rec 2006; 81: 24-32.
49. Galazka AM, Robertson SE. Diphtheria: changing patterns in the developing world and the industrialized world. Eur J Epidemiol 1995; 11: 107-117
50. Galazka AM, Robertson SE, Oblapenko GP. Resurgence of diphtheria. Eur J Epidemiol 1995; 11: 95-105.
51. Salleras L, Vidal J, Plans P, Campins M, Domínguez A, Bayas JM. Bajos niveles de protección inmunitaria frente a la difteria en la población adulta de Cataluña (España). Med Clin (Bare) 1998; 111: 692-695
52. Jiménez R, Larrauri A, Carrasco P, Esteban J, Gómez- López LL, Gil A. Influenza coverages in Spain and vaccination-related factors in the subgroup aged 50-64 years. Vaccine 2003; 21: 3550-3555
53. Salleras L. Las personas del grupo de edad de 50 a 64 años: nueva indicación de la vacuna antigripal. Vacunas 2006; 7: 1-3.
54. Domínguez A, Juncá S, Tresserres R, Batalla J, Salleras L. Influenza vaccination: the prevalence of risk factors in persons aged 50 years and more in Catalonia. Vacunas 2003; 4: 114-118
55. CDC. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005; 54 (RR-8): 1-40.
56. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ et al. Influenza-associated hospitalizations in the United States. JAMA. 2004; 292: 1333-1340
57. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-186
58. Wilde JA, McMillam JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 282: 908-913
59. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 33: 889-893
60. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. I Occup Environ Med 1997; 39: 408-414
61. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284: 1655-1663
62. Shabas R. Mass influenza vaccination in Ontario: a sensible more. Can Med Assoc J 2001; 164: 36-37 (Pubitemid 32094882)
63. Demicheli V. Mass influenza vaccination in Ontario: is it worthvwhile? Can Med Assoc J 2001; 164: 36-37
64. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity metaanalysis. Gerontology 2003; 49: 177-184
65. De Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005; 23 (Suppl. 1): S39-S49.
66. Bruguera M. Sánchez Tapias JM. Epidemiología de la hepatitis B en España. Med Clin (Barc) 1990; 95: 470-475
67. Domínguez A, Vidal J, Bruguera M, Salleras L. Epidemiología de las hepatitis virales. Enf Infecc Microbiol Clin 1995; 13: 50-61.
68. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-841
69. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N et al. Prevention of hepatitis B with vaccine: report from the Center for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982; 97: 362-366
70. Crosnier J, Jüngers P, Couroucé A-M, et al. Randomised placebocontrolled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I. Medical staff. Lancet 1981; 1: 455-459
71. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209-214
72. Chan CY, Lee SD, Lo KJ. Legend of hepatitis B vaccination: the Taiwan experience. Gastroenterol Hepatol 2004; 19: 121-126
73. Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 2000; 181: 413-418
74. CDC Incidence of acute hepatitis B. United States 1990-2002. MMWR 2004; 52: 1252-1254
75. Salleras L, Domínguez A, Bruguera M, Cardeñosa N, Batalla J, Carmona G et al. Dramatic decline in acute hepatitis B infection and disease incidence rates among adolescents and young people after twelve years of a mass hepatitis B vaccination programme of preadolescents in the schools of Catalonia. Vaccine 2005; 23: 2181-2184
76. European Consensus Groups on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-565
77. Lopalco PL, Salleras L, Barbuti S, Germinario C, Bruguera M, Buti M et al. Hepatitis A and B in children and adolescents-what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 2000; 19: 470-474
78. Salleras L, Bruguera M, Vidal J, Taberner JL, Plans P, Jiménez de Anta MT et al. Cambio en el patrón epidemiológico de la hepatitis A en Cataluña (España). Med Clin (Barc) 1992; 99: 87-89
79. Amela C, Pachon L, Bueno R, Domínguez C, Martínez Navarro F. Trends in hepatitis A virus infecions in reference to the process of urbanization in the greater Madrid area (Spain). Eur J Epidemiol 1995; 11: 569-573
80. Domínguez A, Bruguera M, Plans P, Costa J, Salleras L. Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of virosomal hepatitis A immunization. J Med Virol 2004; 73: 172-176
81. Salleras L, Bruguera M, Buti M, Domínguez A, Vidal J, Navas E et al. Hepatitis A vaccination policy in Catalonia (Spain). Vacunas 2000; 1: 30-35
82. Gil A, González A, San-Martin M, Carrasco P. Hospitalizaciones por hepatitis A en España 1995-1998. Vacunas 2004; 5: 31-34
83. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-1334
84. Pérez OM, Herzog C, Zellmeyer M, Loaisiga A, Frosner G, Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo controled trial. J Infect Dis 2003;188:671-677
85. Domínguez A, Oviedo M, Carmona G, Batalla J, Bruguera M, Salieras L et al. Impact and effectiveness of a mass vaccination programme of preadolescents seven years after introduction. JAMA 2001; 286: 2968-2973
86. Van Damme P, Van Merck KV. Effect of hepatitis A vaccination programs. JAMA 2005; 294: 246-248
87. Rodríguez C, Basile L, Urbiztondo L, Borras E, Batalla J. Vacunación antihepatitis A ¿Selectiva o universal? Vacunas 2009; 10: 4-8.
88. Domínguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 2003; 21: 698-701.
89. Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 2004; 22: 4342-4350
90. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005; 294: 194-201.
91. Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis 2008; 197: 1282-1288
92. Dienstag JL. Hepatitis A: the vaccine dividend. J Infect Dis 2008; 197: 1220-1222
93. Averhoff F, Shapiro CN, Bell BP, Hyams I, Burd L, Deladisma A et al. Control of hepatitis A through routine vaccination of children. JAMA 2001; 286: 2968-2973
94. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006; 55(No. RR-7): 1-23.
95. Lieberman JM, Word BM, Jacobs RJ, Dagan R, Marchant CD. Universal hepatitis A vaccination in the United States: a call for action. Ped Infect Dis J 2008; 27: 287-291
96. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294: 202-210
97. Chodick G, Heymann AD, Ashkenazi S, Kokia E, Shalev V. Longterm trends in hepatitis A incidence following the inclusion of Hepatitis A vaccine in the routine nationwide immunization program. J Viral Hepat 2008; 15(supl. 2): 62-65
98. Maclntyre CR, Burgess MA, Hull B, McIntyre PB. Hepatitis A vaccination options for Australia. J Paediatr Child Health 2003; 39: 83-87
99. Lopalco PL, Prato R, Chironna M, Germinarlo C, Quarto M. Control of hepatitis a by universal vaccination of adolescents, puglia, Italy. Emerg Infect Dis 2008; 14: 526-528
100. Salleras L, Domínguez A. Vacuna frente a la hepatitis A en la adolescencia y la edad adulta joven. Vacunas 2006; 7(supl.1): 37-43.
101. Salleras L. Vacunación universal frente a la hepatitis A. Vacunas 2009; 10: 1-3.
102. Navas E, Salleras L, Gisbert R, Domínguez A, Bruguera M, Rodríguez G et al. Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools. Vaccine 2005; 23: 2185-2189
103. Belmaker I, Dukhan L, Yosef Y, Leventhal A, Dagan R. Elimination of hepatitis a infection outbreaks in day care and school settings in southern Israel after introduction of the national universal toddler hepatitis a immunization program. Pediatr Infect Dis J 2007; 26: 36-40.
104. Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck T et al. International Consensus Group of Hepatitis A Virus Immunity. Hepatitis A booster vaccination: is there a need? Lancet 2003; 362: 1065-1071
105. Moraga F, Campins M. Vacuna de la varicela. Una inmunización del niño y del adutlo. Enfer Infec Microbiol Clin 2000; 18: 516-518
106. Salleras L, Salleras M, Domínguez A, Prat A, Navas E. Varicela en el adolescente y adulto: carga de la enfermedad y estrategias de prevención mediante la vacunación. Vacunas 2005; 3: 92-100.
107. Salleras L, Salleras M, Prat A, Garrido P, Domínguez A. Vacuna frente al virus de la varicela zoster. Enferm Infecc Microbiol Clin 2007; 25 (supl. 1): 29-47.
108. Guide for Adult Immunization. Third edition. Philadelphia: American College of Physicians,1994.
109. De Juanes JR, Gil A, Sanmartín M, González A, Esteban J, García de Cades A. Seroprevalence of varicella antibodies in healthcare workers and health sciences students. Reliability of self-reported history of varicella. Vaccine 2005; 23: 1434-1436
110. Salleras L, Dominguez A, Vidal J, Plans P, Salleras M, Taberner JL. Seroepidemiology of Varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 2001; 19: 183-188
111. Seward J, Galil K, Wharton M. Epidemiology of varicella. In: Arvin AM, Gershon AA editors. Varicella-zoster virus. Cambridge University Press 2000; p. 206-219
112. Gil A, Gonzalez A, Oyaguez I, San-Martín M, Carrasco P. The burden of severe varicella in Spain, 1995-2000 period. Eur J Epidemiol 2004; 19: 699-702.
113. Gil A, San-Martin M, Carrasco P, Gonzalez A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 2004; 22: 3947-3951
114. Varis T, Vesikari T. Efficacy of High-Titer Attenuated Varicella Vaccine in Healthy Young Children. J Infect Dis 1996:174 (Supl. 3): 330-334
115. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitsgerald AJ et al. Live attenuated varicella vaccine: efficacy trial in healthy children. N Engl J Med 1984; 310: 1409-1415
116. Galil K, Fair E, Mountcastle N, Britz P, Seward J. Yonger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis 2002; 186: 102-105
117. TugweLL BD, Lee LE, Lorber K, Gillette H, Lorber EM, Hedberg K et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics 2004; 113: 455-459
118. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997; 278: 1495-1499
119. Clements DA, Moreira SP, Coplan PM, Bland CL, Walter EB. Postlicensure study of varicella vaccine effectiveness in a day care setting. Pediatric Infect Dis J 1999; 18: 1047-1050
120. Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C et al. Postexposure effectiveness of varicella vaccine. Pediatrics 2000; 105: 84-88
121. Vazquez M, La Russa PS, Gershon AA, Steinberg SP, Freudingman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Egl J Med 2001; 344: 955-960
122. Passwell JH, Hemo B, Levi Y, Ramon R, Friedman N, LernerGeva L. Use of a computerized database to study the effectiveness of an attenuated varicella vaccine. Pediatr Infect Dis J 2004; 23: 221-226
123. Sheffer R, Segal D, Rahamani S, Dalal I, Linhart Y, Stein M et al. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J 2005; 24: 434-437
124. Salleras L, Sanchez F, Prats G, Garau X. Vacuna antineumocócica 23-valente. En: Salleras L, editor. Vacunaciones preventivas. 2 ed. Masson, Barcelona 2003; p. 363-398
125. Domínguez A, Salleras L, Fedson D, Izquierdo C, Ruiz L, Ciruela P et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia. A case control study. Clin Infect Dis 2005; 40: 1250-1257
126. Domínguez A et al. Effectiveness of 23-valent pneumococcal vaccine in the prevention of all-causes pneumonia. A case control study. JAMA 2009 (en prensa).
127. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunizations Practices (ACTP). MMWR 1997; 46 (RR-8): 1-24.
128. The US Preventive Task Force. Guide to clinical preventive services. Second edition. Baltimore, Williams and Wilkins, 1996.
129. Canadian Task Force on the Periodic health Examination. The Canadian guide to clinical preventive health care. Otawa, Canada, Communication Group Publishing, 1994; 386-395
130. Salleras L, Domínguez A. Vacuna antisarampión. En: Salleras L, editor. Vacunaciones Preventivas. Principios y Aplicaciones. 2 ed. Barcelona: Masson, 2003; p. 217-243
131. Salleras L, Vidal J, Asensi F, Gentile A. Vacuna antirrubeola. En: Salleras L, editor. Vacunaciones Preventivas. Principios y aplicaciones. 2 ed. Barcelona: Masson, 2003; p. 245-263
132. Amela C, Pachón I. Estudio seroepidemiológico y situación de las enfermedades vacunables en España. Madrid: Ministerio de Sanidad y Consumo, 2000.
133. Lowy DR, Howley PH. Papillomaviruses. In: Knipe DM, Howley PH, editors. Fields Virology. Philadelphia: Lippincott, William & Wilkins, 2001; p. 2231-2264
134. Castellsagué X, Bosch FX. Vacunas frente al virus del papiloma humano. Enferm Infecc Microbiol Clin 2007; 25(supl. 5): 65-77.
135. Dunne EF, Markowitz LE. Genital human pa pillomavirus infection. Clin Infect Dis 2006; 43: 624-629
136. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116: 1167-1173
137. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
138. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 1999; 26(supl. 4): 2-7.
139. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32(supl. 1): 16-24.
140. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527
141. Shew ML, Fortenberry JD. HPV infection in adolescents: natural history, complications, and indicators for viral typing. Semin Pediatr Infect Dis 2005; 16: 168-174
142. Ault KA. Epidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract. Infect Dis Obstet Gynecol 2006; 2006: 40470.
143. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E et al. The burden of genital warts: A study of nearly 70,000 women from the general female population in the 4 nordic countries. J Infect Dis 2007: 196: 1447-1454
144. Daward M, Deeks S, Dobson S. Human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ 2007; 177: 456-461
145. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364: 1757-1765
146. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278
147. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170
148. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943
149. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against highgrade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-1702
150. CDC. Quadrivalent human papillomarivus vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR 2007; 56 (RR02); 1-24.
151. Halsey NA. The human papillomavirus vaccine and risk of anaphylaxis. CMAJ 2008; 179: 509-510
152. MacDonald N, Stanbrook MB, Hebert PC. Human papillomavirus vaccine risk and reality. CMAJ 2008; 179: 503.
153. Kang LW, Crawford N, Tang ML, Buttery J, Royle J, Gold M et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ 2008; 337: a2642. doi: 10.1136/bmj.a2642.
154. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S. New South Wales Health HPV Adverse Events Panel. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008; 179: 525-533
155. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Nota informativa 23 de abril de 2009 sobre los episodios de Valencia y Baleares ocurridos tras la administración de la vacuna frente al papilomavirus humano. http://www.msc.es/gabinetePrensa/notaPrensa/desarrolloNotaPrensa.jsp?id= 1466
156. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255
157. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-5583
158. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD et al. Comparisson of the inmunogenicity and reactogenicity of a prophylactic quadrvalent human papillomavirus ( types 6, 11, 16, and 18) L1 virus -likeparticles vaccine in male and female adolescents and young adult women. Pediatrics 2008; 118: 2135-2145
159. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11116/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-4939
160. Giannini S L, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F et al. Enhanced humoral and memory B cellular immunity using VPH 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared with aluminium salt only. Vaccine 2006; 24: 5937-5949
161. The future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927
162. Ault KA. Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-1868
163. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007; 177: 469-479
164. La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W. HPV vaccine efficacy in preventing persistent cervical HPV infection: A systematic review and meta-analysis. Vaccine 2007; 25: 8352-8358
165. Bosch FX, Castellsague X, de Sanjose S. HPV and cervical cancer: Screening or vaccination? Br J Cancer 2008; 98: 15-21.
166. C SA ,Teixeria J, Wheeler CM et al. Substancial impact on precancerous lesions and HPV infections throug 5.5 years in women vaccinated with the HPV-16-18 L1 ASO4 candidate vaccine. American Assotiation for Cancer Research Annual Meeting, Los Angeles Ca 2007, (Abstract 4900).
167. Villa LL, Costa RL, Petta CA, Andrade RA, Paavonen J, Iversen O-E et al. High sustained efficacy of a proplylactic quadrivalent human papillomavirus types 61 11/16/18 L1 virus like particule vaccine throug five years of follow-up. Br J Cancer 2006; 951459-951466
168. Herrero R. Human papillomavirus (HPV) vaccines: limited crossprotection against additional HPV types. J Infect Dis 2009; 199: 919-922
169. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, HernandezAvila M, Wheeler CM et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199: 926-935
170. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, HernandezAvila M, Perez G et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199: 936-944
171. Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 2008; 7: 1465-1473
172. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008; 110(3 Suppl 1): S18-25.
173. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-789
174. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-1923
175. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37-48.
176. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX et al. Projected clinical benefits and cost-effectiveness of a human papi llontavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-615
177. Langeron N, Remy V, Oyee J, San-Martín M, Cortés J, Olmos L. Análisis de coste-efectividad de la vacunación frente al virus del papiloma humano tipos 6, 11, 16 y 18 en España. Vacunas 2008; 9: 3-11.